Radionuclide therapy with [223Ra] radium chloride is now available to patients of NMIC Radiology

Dear friends! We are pleased to inform you that radionuclide therapy [223Ra] with radium chloride is now available to patients of our Center. This type of treatment is indicated for patients with castration-resistant prostate cancer with metastatic bone damage, usually accompanied by an increase in bone metabolism with increased mineralization. As a chemical analog of calcium, [223Ra] radium chloride actively accumulates in areas with increased bone mineralization, exerting a damaging effect on tumor cells.

Radionuclide therapy with [223Ra] radium chloride is performed at the P. A. Hertsen Moscow Research Institute of Radiology, a branch of the National Research Center of Radiology of the Ministry of Health of the Russian Federation. Treatment is carried out under the state guarantee program (MHI) or at the patient’s personal expense (for foreign citizens). The course of treatment is designed for 6 injections with an interval of 28 days.

To consider the possibility of radionuclide therapy with radium chloride, please contact the unified contact center by phone +7 (495) 150-11-22 and consult an oncologist.

️For consultation, the patient must provide medical documentation containing up-to-date information about the treatment performed, and the results of studies performed with a limitation period of no more than 30 days at the time of treatment:
– general clinical blood test (with determination of the absolute number of neutrophils, platelets, hemoglobin levels)–
– biochemical blood test (with determination of creatinine, ALT levels, AST)–
– blood test with assessment of PSA and testosterone levels–
– CT scan of the chest, abdominal and pelvic organs (preferably with intravenous X-ray contrast agent in the absence of contraindications) or (preferably) PET/CT scan with 68Ga-PSMA or 18F-PSMA;
– osteoscintigraphy (required on an electronic carrier in DICOM format, if necessary, it can be performed in the Department of Radionuclide Therapy and Diagnostics of the P. A. Hertsen Moscow Oncology Research Institute).

Press Service of the National Research Center of Radiology of the Ministry of Health of the Russian Federation